A small randomized trial in patients with post-COVID syndrome has found that hyperbaric oxygen therapy (HBOT) promotes restoration of the heart's ability to contract properly, according to data presented today at EACVI 2023, a scientific congress of the European Society of Cardiology.
The study enrolled 60 patients in a randomized controlled double-blind trial that measured how and if HBOT helped patients who have mild to moderate long COVID. The therapy involves inhalation of 100% pure oxygen at high pressure, and has been shown to help non-healing wounds, radiation injury, and other types of infection by increasing oxygen delivery to damaged tissues.
All patients had five sessions per week over 8 weeks, for a total of 40 sessions. The HBOT group received 100% oxygen through a mask at a pressure of 2 atmospheres for 90 minutes, with 5-minute air breaks every 20 minutes. The control group breathed 21% oxygen by mask at 1 atmosphere for 90 minutes. Echocardiograms were done before the first session (baseline) and 1 to 3 weeks after the last session.
More research is needed to collect long-term results and determine the optimal number of sessions.
Echocardiography measured the heart's ability to contract and relax based on left ventricular global longitudinal strain (GLS). At baseline, nearly half of study participants (29 of 60; 48%) had reduced GLS. In healthy adults, GLS should be approximately -20%.
In the HBOT group, GLS significantly increased from -17.8% at baseline to -20.2% after the intervention. In the control group the GLS had no significant differences.
"The findings suggest that HBOT promotes recovery of cardiac function in patients with post-COVID syndrome," said Marina Leitman, MD, of the Sackler School of Medicine, Tel Aviv University and Shamir Medical Centre, Be'er Ya'akov, Israel. "More research is needed to collect long-term results and determine the optimal number of sessions for maximum therapeutic effect."